Synthetic human monoclonal antibodies toward staphylococcal enterotoxin B (SEB) protective against toxic shock syndrome.

Integrated Biotherapeutics, Inc, Gaithersburg, Maryland 20878, USA.
Journal of Biological Chemistry (Impact Factor: 4.6). 05/2012; 287(30):25203-15. DOI: 10.1074/jbc.M112.364075
Source: PubMed

ABSTRACT Staphylococcal enterotoxin B (SEB) is a potent toxin that can cause toxic shock syndrome and act as a lethal and incapacitating agent when used as a bioweapon. There are currently no vaccines or immunotherapeutics available against this toxin. Using phage display technology, human antigen-binding fragments (Fabs) were selected against SEB, and proteins were produced in Escherichia coli cells and characterized for their binding affinity and their toxin neutralizing activity in vitro and in vivo. Highly protective Fabs were converted into full-length IgGs and produced in mammalian cells. Additionally, the production of anti-SEB antibodies was explored in the Nicotiana benthamiana plant expression system. Affinity maturation was performed to produce optimized lead anti-SEB antibody candidates with subnanomolar affinities. IgGs produced in N. benthamiana showed characteristics comparable with those of counterparts produced in mammalian cells. IgGs were tested for their therapeutic efficacy in the mouse toxic shock model using different challenge doses of SEB and a treatment with 200 μg of IgGs 1 h after SEB challenge. The lead candidates displayed full protection from lethal challenge over a wide range of SEB challenge doses. Furthermore, mice that were treated with anti-SEB IgG had significantly lower IFNγ and IL-2 levels in serum compared with mock-treated mice. In summary, these anti-SEB monoclonal antibodies represent excellent therapeutic candidates for further preclinical and clinical development.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Staphylococcal enterotoxin B (SEB) is a superantigen that cross-links the major histocompatibility complex class-II (MHC- II) and specific V-β chains of the T-cell receptor (TCR) thus forming a ternary complex. Developing neutralizing monoclonal antibodies (mAb) to disrupt the ternary complex and abrogate the resulting toxicity is a major therapeutic challenge because SEB is effective at very low concentrations. We show that combining two SEB-specific mAbs enhances their efficacy even though one of the two mAbs by itself has no effect on neutralization. Crystallography was employed for fine- mapping of conformational epitopes in binary and ternary complexes between SEB and Fab fragments. NMR spectroscopy was used to validate and identify subtle allosteric changes induced by mAbs-binding to SEB. The mapping of epitopes established that combination of different mAbs can enhance efficacy of mAb-mediated protection from SEB induced lethal shock by two different mechanisms: one mAb cocktail promoted clearance of the toxin both in vitro and in vivo by FcR mediated crosslinking and clearance; whereas the other mAb cocktail induced subtle allosteric conformational changes in SEB that perturbed formation of the SEB:TCR:MHC-II trimer. Finally structural information accurately predicted mAb binding to other superantigens that share conformational epitopes with SEB. Fine mapping of conformational epitopes is a powerful tool to establish the mechanism and optimize the action of synergistic mAb combinations. Copyright © 2015, The American Society for Biochemistry and Molecular Biology.
    Journal of Biological Chemistry 01/2015; 290(11). DOI:10.1074/jbc.M114.630715 · 4.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Due to the fast-acting nature of ricin, staphylococcal enterotoxin (SEB), and Clostridium perfringens epsilon toxin (ETX), it is necessary that therapeutic interventions following a bioterrorism incident by one of these toxins occur as soon as possible after intoxication. Moreover, because the clinical manifestations of intoxication by these toxins are likely to be indistinguishable from each other, especially following aerosol exposure, we have developed a cocktail of chimeric monoclonal antibodies that is capable of neutralizing all three toxins. The efficacy of this cocktail was demonstrated in mouse models of lethal dose toxin challenge.
    Toxicon 09/2014; 92. DOI:10.1016/j.toxicon.2014.09.006 · 2.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We postulated that the activation of proinflammatory signaling by USA300-MRSA is a major factor in the pathogenesis of severe pneumonia and a target for immunomodulation. Local activation of T cells in the lung was a conserved feature of multiple strains of S. aureus, in addition to USA300. The pattern of Vβ chain activation was consistent with known superantigens, but deletion of SelX or SEK and SEQ was not sufficient to prevent T cell activation, indicating the participation of multiple genes. Using Rag2(-/-), Cd4(-/-) and Cd28(-/-) mice we observed significantly improved clearance of MRSA from the airways and decreased lung pathology as compared to wild type controls. The improved outcome correlated with decreased production of proinflammatory cytokines (TNF, KC, IL-6 and IL-1β). Our data suggest that T cell-mediated hypercytokinemia induced by USA300 contributes pathogenesis and may provide a therapeutic option to improve outcome from this common infection in a clinical setting.
    The Journal of Infectious Diseases 09/2014; 211(5). DOI:10.1093/infdis/jiu525 · 5.78 Impact Factor